KR20070092329A - 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는요산산화효소 - Google Patents

비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는요산산화효소 Download PDF

Info

Publication number
KR20070092329A
KR20070092329A KR1020077018682A KR20077018682A KR20070092329A KR 20070092329 A KR20070092329 A KR 20070092329A KR 1020077018682 A KR1020077018682 A KR 1020077018682A KR 20077018682 A KR20077018682 A KR 20077018682A KR 20070092329 A KR20070092329 A KR 20070092329A
Authority
KR
South Korea
Prior art keywords
uricase
peg
conjugates
aggregates
uricases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077018682A
Other languages
English (en)
Korean (ko)
Inventor
메리 알. 셔먼
마아크 지. 피. 사이퍼
엘. 데이비드 윌리엄스
마이클 에스. 허쉬필드
수잔 제이. 켈리
Original Assignee
마운틴 뷰 파마슈티컬즈 인크.
듀크 유니버서티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마운틴 뷰 파마슈티컬즈 인크., 듀크 유니버서티 filed Critical 마운틴 뷰 파마슈티컬즈 인크.
Publication of KR20070092329A publication Critical patent/KR20070092329A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020077018682A 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는요산산화효소 Ceased KR20070092329A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US09/501,730 2000-02-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027010189A Division KR100884724B1 (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소

Publications (1)

Publication Number Publication Date
KR20070092329A true KR20070092329A (ko) 2007-09-12

Family

ID=23994789

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077018682A Ceased KR20070092329A (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는요산산화효소
KR1020087024272A Expired - Lifetime KR101054247B1 (ko) 2000-02-10 2001-02-07 정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법
KR1020027010189A Expired - Lifetime KR100884724B1 (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020087024272A Expired - Lifetime KR101054247B1 (ko) 2000-02-10 2001-02-07 정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법
KR1020027010189A Expired - Lifetime KR100884724B1 (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소

Country Status (27)

Country Link
US (3) US6783965B1 (enExample)
EP (3) EP2305819B1 (enExample)
JP (2) JP5165826B2 (enExample)
KR (3) KR20070092329A (enExample)
CN (2) CN101735991B (enExample)
AT (1) ATE463576T1 (enExample)
AU (3) AU4997501A (enExample)
BE (1) BE2013C045I2 (enExample)
BR (1) BRPI0108386B8 (enExample)
CA (1) CA2398679C (enExample)
CY (3) CY1110142T1 (enExample)
CZ (1) CZ304864B6 (enExample)
DE (1) DE60141742D1 (enExample)
DK (3) DK1254237T3 (enExample)
ES (2) ES2343105T3 (enExample)
FR (1) FR13C0036I2 (enExample)
HU (1) HU227127B1 (enExample)
IL (3) IL151065A0 (enExample)
LU (1) LU92237I2 (enExample)
MX (1) MXPA02007545A (enExample)
NZ (1) NZ520434A (enExample)
PL (1) PL208064B1 (enExample)
PT (2) PT1254237E (enExample)
RU (3) RU2352354C2 (enExample)
TW (2) TW200914617A (enExample)
WO (1) WO2001059078A2 (enExample)
ZA (1) ZA200207206B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004145A (ko) * 2019-05-10 2022-01-11 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) 폴리에틸렌 글리콜로 변형된 요산 산화효소

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
JP2002524053A (ja) 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT2158923E (pt) 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
RU2278680C2 (ru) * 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
US7229810B2 (en) 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
EA010016B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Новые модифицированные полиэтиленгликолем соединения и их применение
BRPI0411166A (pt) 2003-05-12 2006-07-18 Affymax Inc composto compreendendo uma parcela de peptìdeo, uma parcela espaçadora e uma parcela de polìmero solúvel em água e composição farmacêutica compreendendo tal composto
BRPI0411172A (pt) * 2003-05-12 2006-07-18 Affymax Inc peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
PT1663281E (pt) * 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP2279756A2 (en) * 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CA2604545A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2538357T3 (es) 2005-04-11 2015-06-19 Crealta Pharmaceuticals Llc Formas variantes de urato oxidasa y uso de las mismas
US20090081122A1 (en) * 2005-05-23 2009-03-26 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2013225B1 (en) * 2006-04-12 2014-12-17 Crealta Pharmaceuticals LLC Purification of proteins with cationic surfactant
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CA2913476A1 (en) * 2013-06-07 2014-12-11 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
AU2018297309A1 (en) 2017-07-07 2020-01-30 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
BR112023002458A2 (pt) 2020-08-10 2023-05-02 Horizon Therapeutics Usa Inc Métodos de tratamento da gota
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
CN117051026A (zh) * 2022-05-06 2023-11-14 江苏恰瑞生物科技有限公司 一种特异性尿酸结合物固定化树脂及其制备方法和应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (enExample)
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
KR0159107B1 (ko) 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
SU1730145A1 (ru) * 1990-05-04 1992-04-30 Всесоюзный научно-исследовательский институт текстильно-галантерейной промышленности Способ стабилизации уриказы
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
AU6586394A (en) * 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10510516A (ja) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
AU725133B2 (en) 1997-01-15 2000-10-05 Polaris Group Modified tumor necrosis factor
ATE274522T1 (de) * 1998-06-01 2004-09-15 Genentech Inc Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT2158923E (pt) * 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
JP2002524053A (ja) 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
RU2278680C2 (ru) 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
WO2014187953A1 (en) 2013-05-24 2014-11-27 Zentrum Mikroelektronik Dresden Ag Non pwm digital dc-dc converter

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004145A (ko) * 2019-05-10 2022-01-11 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) 폴리에틸렌 글리콜로 변형된 요산 산화효소

Also Published As

Publication number Publication date
CY2013028I1 (el) 2015-11-04
JP5341945B2 (ja) 2013-11-13
HK1143989A1 (en) 2011-01-21
EP1254237A2 (en) 2002-11-06
RU2009104003A (ru) 2010-08-20
RU2557318C9 (ru) 2015-09-10
BR0108386A (pt) 2002-10-29
AU2009212900A1 (en) 2009-10-01
PT2305819E (pt) 2015-06-01
ES2524153T3 (es) 2014-12-04
EP2305819B1 (en) 2014-11-12
US6783965B1 (en) 2004-08-31
EP1254237B1 (en) 2010-04-07
WO2001059078A3 (en) 2002-03-07
HU227127B1 (en) 2010-07-28
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
CN100491532C (zh) 2009-05-27
TWI322184B (en) 2010-03-21
IL193365A (en) 2011-08-31
EP2196538A1 (en) 2010-06-16
DK2196538T3 (en) 2015-01-05
FR13C0036I2 (fr) 2014-05-16
PT1254237E (pt) 2010-06-07
HUP0204544A3 (en) 2007-05-02
PL208064B1 (pl) 2011-03-31
RU2281954C2 (ru) 2006-08-20
HUP0204544A2 (en) 2003-05-28
CN101735991A (zh) 2010-06-16
ZA200207206B (en) 2003-05-06
WO2001059078A2 (en) 2001-08-16
KR20080098686A (ko) 2008-11-11
CA2398679C (en) 2015-11-17
ES2343105T8 (es) 2013-07-15
MXPA02007545A (es) 2002-12-13
IL193365A0 (en) 2009-02-11
NZ520434A (en) 2004-05-28
FR13C0036I1 (fr) 2013-08-09
JP2003521937A (ja) 2003-07-22
HK1144701A1 (en) 2011-03-04
IL151065A (en) 2008-12-29
US7927852B2 (en) 2011-04-19
BRPI0108386B8 (pt) 2021-05-25
CY2013028I2 (el) 2015-11-04
DE60141742D1 (de) 2010-05-20
EP2196538B1 (en) 2014-10-01
BR0108386C1 (pt) 2011-12-20
LU92237I2 (fr) 2013-09-03
ATE463576T1 (de) 2010-04-15
US20080057048A1 (en) 2008-03-06
CZ20022982A3 (cs) 2003-01-15
JP2011188861A (ja) 2011-09-29
BR0108386B1 (pt) 2017-10-31
CN101735991B (zh) 2013-09-11
CA2398679A1 (en) 2001-08-16
KR100884724B1 (ko) 2009-02-19
RU2006107110A (ru) 2007-09-20
US8921064B2 (en) 2014-12-30
DK2305819T3 (en) 2015-01-05
DK1254237T3 (da) 2010-07-19
JP5165826B2 (ja) 2013-03-21
CZ304864B6 (cs) 2014-12-17
CN1423699A (zh) 2003-06-11
CY1117264T1 (el) 2017-04-26
KR101054247B1 (ko) 2011-08-08
PL358539A1 (en) 2004-08-09
EP2305819A1 (en) 2011-04-06
TW200914617A (en) 2009-04-01
US20110287466A1 (en) 2011-11-24
RU2352354C2 (ru) 2009-04-20
HK1155203A1 (en) 2012-05-11
BE2013C045I2 (enExample) 2020-06-24
HK1056742A1 (zh) 2004-02-27
ES2343105T3 (es) 2010-07-23
IL151065A0 (en) 2003-04-10
AU2009212900B2 (en) 2011-12-08
AU4997501A (en) 2001-08-20
AU2001249975B2 (en) 2006-06-08
CY1110142T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
KR100884724B1 (ko) 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소
US20180223263A1 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
KR100614212B1 (ko) 피이지-유레이트 옥시데이즈 접합체 및 그의 이용
AU2006203252B2 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1144701B (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1056742B (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070814

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071112

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080929

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090430

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100430

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090430

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20080929

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20071112

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20100802

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100430

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120330

Appeal identifier: 2010101005893

Request date: 20100802

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20100901

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20100901

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20100802

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20081229

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080509

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20101011

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100802

Effective date: 20120330

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20120402

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20100802

Decision date: 20120330

Appeal identifier: 2010101005893

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20120402

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20121115

Appeal identifier: 2012201005097

Request date: 20120614

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120614

Effective date: 20121115

PJ1302 Judgment (patent court)

Patent event date: 20121205

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20120614

Decision date: 20121115

Appeal identifier: 2012201005097

Appeal kind category: Appeal against decision to decline refusal